使用RBD4059抑制XI因子:一种具有强大和持久抗血栓作用的新型GalNAc-siRNA
Junshi Liang1, Sofia Nilsson2, Johannes Wikström3
1Suzhou Ribo Life Science Co Ltd, Kunshan City, Jiangsu, China.
JACC. Basic to translational science
|June 25, 2025
概括
一种新药,RBD4059,针对抗血栓治疗的凝血因子XI (FXI). 它表现出强大的FXI抑制和抗血栓作用,具有较低的出血风险,提供了一个有前途的新型抗凝药选择.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血栓形成研究研究
- 药物开发 药物开发
背景情况:
- 凝血因子XI (FXI) 是抗血栓性药物的潜在目标.
- 目前的抗凝血剂携带出血的风险.
- 需要更安全,更有效的抗血栓治疗.
研究的目的:
- 为了评估RBD4059,一个新的GalNAc-siRNA针对FXI.
- 评估RBD4059作为抗血栓剂的疗效和安全性.
主要方法:
- 在小鼠和非人类灵长类动物模型中使用RBD4059.
- 评估FXI抑制和持续时间.
- 在血栓形成模型中评估抗血栓活性.
- 在小鼠尾部出血模型中分析出血风险.
主要成果:
- RBD4059在小鼠和子中显示出强大且持久的FXI抑制.
- 该药在临床前模型中表现出显著的抗血栓作用.
- 在小鼠尾部出血模型中没有观察到长时间出血.
结论:
- RBD4059是第一个针对FXI的GalNAc-siRNA进入临床开发.
- 作为一种安全有效的抗血栓性药物,RBD4059具有较低的出血风险.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
924
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
924
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
655
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Experimental RNAi
6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K


